Jennifer Lopez, director, solutions delivery at Maetrics discusses why heightened due diligence is needed for pharmaceutical manufacturers during mergers and acquisitions.
M&A
Mergers and acquisitions (M&A) within the global pharmaceutical industry are prolific; in fact, pharmaceutical companies probably face more M&A activity than any other industry. Typically the main driver for changes in the pharmaceutical industry is the ever-increasing prices of drug-development as a lot of companies fail to keep up with the demanding costs of R&D to find new and innovative compounds for the market. However, as the pharmaceutical industry expands, European and US-based manufacturers are creating increasingly globalised supply chains which increases the potential risk for manufacturers to mismanage their compliance procedures.